Analysis of the optical waveform generated during global coagulation assays, such as This review has been written using an exhaustive analysis of orig- 
| INTRODUCTION
Coagulation is a highly complex physiological mechanism that involves multiple plasma proteins, cellular components and the vessel wall.
Increasing coagulation and fibrinolysis knowledge has led to major improvements in clinical practice decisions, resulting in optimized and safer patient management in both haemorrhagic and thrombotic set- be predicted by CWA. 1, 2 The management of haemophilia treatments and bypass therapy in HA patients with inhibitors is also of great interest. 3, 4 Additionally, it has been shown that CWA can help in the early diagnosis and prognosis of sepsis and disseminated intravascular coagulation (DIC). 5, 6 This review has been written using an exhaustive analysis of orig- 
| WHAT IS CLOT WAVEFORM ANALYSIS?
Clot waveform analysis corresponds to the extended study of the slope generated by an optical detection system during routine co- 
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The coagulation process can be divided into 3 distinct periods, the precoagulation phase, the coagulation phase and the postcoagulation phase. These 3 phases can be characterized by parameters defining the time interval, the rate, the "slope" and the magnitude of the sig- Denomination of these parameters varies depending on whether the recorded signal is transmittance or absorbance. In the case of transmittance, which is the most widely reported detection system in the literature, maximum velocity is called "Min1," maximum acceleration is called "Min2," and maximum deceleration is called "Max2." The normal transmittance waveform pattern is illustrated in Figure 1 . The pattern of the absorbance detection system is the reverse of the transmittance pattern. Hence, maximum velocity, maximum acceleration and maximum deceleration are called "Max1," "Max2" and "Min2," respectively.
To aid comprehension, transmittance nomenclature will be used in this review.
Besides quantitative parameters reflecting fibrin formation kinetics, CWA is able to identify other potential reactions of interest in clinical practice such as detection of the CRP-VLDL complexes. The formation of these complexes results in the biphasic waveform pattern (BWP). 6 This is of special relevance in the prediction of impending DIC as we will see further in this article.
To carry out CWA, an automated coagulation analyser that uses an optical-based system for clot formation detection is required. The analyser is usually equipped with software that automatically computerizes absorption or transmittance raw data and translates them into CWA parameters. Alternatively, raw data can also be exported and processed by external software. 
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The absolute maximum values of the first and second derivatives of the aPTT curve (Min1 and Min2, respectively) are the most widely used parameters for CWA in the evaluation of low levels of factor VIII and factor IX. However, other sets of parameters can be used for the expression of CWA modifications, as shown in the study led by
Milos.
13 They expressed, with a parameter called Delta, the steepness of the aPTT curve during the coagulation phase. They then showed that Delta is significantly different between severe and nonsevere HA patients and that this parameter could be used to discriminate between those 2 groups of patients with a remarkable sensitivity and specificity (ROC analysis: area under the curve = 0.978, P < .001; sensitivity = 97.3%; specificity = 93.2%). Moreover, they showed that the occurrence of severe clinical events (age of first bleed, number of annual joint bleeds and number of joints with haemophiliac arthroplasty)
is better correlated with the Delta parameter than with FVIII activity assays (either one-stage clotting assay or chromogenic assay). This confirms the potential of aPTT CWA in the prediction of bleeding phenotypes regardless of CWA parameters used to express the results.
Another concept of CWA has been made by Tokunaga et al as they observed different profiles in the second-derivative curves of the aPTT assay: normal pattern, a shoulder type curve and a biphasic type curve with a double peak. The presence of the double peak was associated with severity of intrinsic pathway factor deficiency. In addition, in acquired von Willebrand disease patients, the biphasic pattern is normalized following DDAVP infusions which increase von Willebrand factor levels. considered that the first derivative of the aPTT assay curve represents thrombin activity, the second derivative represents prothrombinase activity, and finally, the third derivative represents tenase activity.
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They correlated the maximum absolute value of the first derivative with the activity of thrombin calculated with a Michaelis-Menten mathematical model and found an excellent correlation (r 2 = 0.95). In addition, this study is the first to present the third derivative as the best parameter correlated with low concentrations of FVIII.
In view of the interest of these parameters in the evaluation of severe haemophilia A and B, the implementation into clinical practice as an aid for determining the bleeding risk should be considered. It could be even more valuable for laboratories which do not have capabilities for measuring FVIII:C or FIX:C. However, aforementioned studies were conducted on small series of patients only. Conducting larger and prospective studies including reliable collection of clinical data should be considered to confirm the potential of clot waveform in haemophilia.
| Replacement therapy management
In 
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It can thus be seen that CWA is a very promising tool for the evaluation of the effects of haemostatic drugs, either for research and development purposes by pharmaceutical companies or in clinical use for the follow-up of patients' haemostasis recovery.
| Disseminated intravascular coagulation and sepsis
Disseminated intravascular coagulation is an acquired disorder of the coagulation and fibrinolytic system, secondary to defined groups of severe diseases such as sepsis or trauma. 
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In a second study led by the same author, the correlation between CWA and DIC diagnosis was assessed in a prospective cohort of 747 patients. The study showed that the sensitivity and specificity of BWP for DIC diagnosis was 97.6% (95% confidence interval [CI]: 85.6%-99.9%) and 98% (95% CI: 96.6%-98.9%), respectively. 5 Toh and colleagues demonstrated that the addition of Ca 2+ in the test sample induces the rapid formation of a precipitate that contains C-reactive protein (CRP) and very low-density lipoprotein (VLDL). The calculated concentration of CRP-VLDL complexes is correlated with turbidity changes in the sample, thus confirming the assumption. 6 Furthermore, VLDL complexed to CRP has been shown to induce a procoagulant effect through enhancement of the prothrombinase complex, by modification of the anionic phospholipid surface. 26 The same group prospectively assessed CWA in 1,187 patients admitted in the ICU over a 24-month period and concluded that CWA predicts DIC outcome more effectively than D-dimer, CRP or VLDL measurements alone. 6 The results also showed that the appearance of BWP preceded, by an average of 18 hours (range 2-47 hours), the time of DIC diagnosis (using Japanese Ministry of Health and Welfare-JMHW-criteria for DIC diagnosis). Furthermore, the quantitation of the degree of abnormality could provide an index for the prediction of the clinical response of DIC to therapy. 27 In this cohort, the overall death rate was found to be 44% for patients who are positive for BWP whereas it was only 25% for patients with a normal aPTT waveform. 28 Another prospective study over 217 consecutive ICU patients demonstrated that the presence of the BWP has a sensitivity of 88% and a specificity of 97% for diagnosis of DIC, as compared to a blind diagnosis based on experts' opinion. 0.948 ± 0.039; P < .01). 34 This finding reinforces what Chopin et al described in a ICU population of 187 consecutive patients: the biphasic aPTT waveform was able to discriminate between patients with severe sepsis and sepsis shock from patients with SRIS and nonsevere sepsis with a sensitivity of 90% (95% CI: 82%-94%) and a NPV of 92% (95% CI: 87%-96%).
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It has also been reported in a non-ICU population that the presence of aPTT BWP is related to the poorest clinical outcomes (infection prevalence, overall mortality). 36 Consecutively, enrolled patients who showed positive aPTT BWP also had positive microbial culture in 67% of cases, whereas only 13% of patients without BWP had positive microbial culture. 32 CWA has been assessed in meningococcal sepsis-affected children. Results showed that the presence of BWP is associated with the poorest outcomes (prolonged hospital stay) and that this convenient assay could facilitate a prompt diagnosis, in combination with procalcitonin measurement. 37 The combination with procalcitonin levels was notably assessed by Zarariah et al and has
demonstrated that, at optimized thresholds, this combination showed enhanced sensitivity of 79% (95% CI: 64%-90%), specificity of 96% (95% CI: 93%-98%) and negative predictive value of 96% (95% CI:
94%-98%).
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Altogether, the cumulative evidences confirm the considerable capacity of CWA in predicting DIC or sepsis. However, this parameter is not actually used in a clinical setting, although the sensitivity has been described as elevated (up to 98%). 28, 29 This may be due to the actual limited number of laboratories providing CWA and to the lake of large prospective confirmatory studies. However, it could be of great interest to implement it in different scores, as the test is inexpensive, easy to perform and has shown high performances for both DIC and sepsis. 39 
| Other potential indications
Since the introduction of the assay into clinical studies, CWA has been assessed to detect procoagulant or prohaemorrhagic patients' status in a variety of disorders.
Lupus anticoagulants (LA) were notably studied with CWA by Su et al 40 Investigation of patients with antiphospholipid antibodies (APA) was performed using both aPTT and PT waveforms. They showed that the slope of the precoagulation phase of PT assay (called slope 1) presents an abnormal result (a difference of more than 2 SD from a healthy group) in 61.5% of patients with APA. In contrast, 5.1% of patients without APA but treated by warfarin, and no healthy patients (untreated by warfarin) present an abnormal slope 1. However, these results were highly reagent-dependent as it has only been observed with the Simplastin ® reagent, and no significant decrease in slope 1 was observed with other thromboplastin reagents. Concerning aPTT assay, none of the extracted parameters consistently distinguished patients with APA from other groups of patients, even aPTT clotting time due to its weak specificity. In other studies, abnormal aPTT waveform
The biphasic waveform pattern could be seen in patients with disseminated intravascular coagulation (DIC) (waveform in dotted line)
has been observed in 25% of patients with APA, 41 but the authors did not determine any aPTT waveform parameter that would allow the segregation of APA-positive patients from DIC patients, as the curve profiles are too similar. 23 A recent study observed that absolute Min1 value of aPTT assay is decreased in patients with both positive LA and clinical antiphospholipid syndrome (2.2 ± 0.5; mean value ± SD), and in patients with LA but without antiphospholipid syndrome (1.6 ± 0.2), compared to normal patients (3.1 ± 0.1). Furthermore, Min1 for patients with mild HA or acquired HA is significantly decreased (1.3 ± 0.2 and 0.9 ± 0.5, respectively) compared to the aforementioned groups.
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However, even if differences are significant, the distribution of Min1 values overlaps, and single CWA testing could not distinguish between patients in the different groups. An atypical pattern for Min1 and Min2 curves has also been observed in patients with LA, but none in normal patients, using silica-based aPTT reagent. 43 This observation is however highly reagent-dependent as ellagic acid reagent produces a similar atypical pattern in normal patients and in LA-positive patients.
Ultimately, many different observations have been made in patients with LA, and further studies are required to confirm these observations and add proof of the interest of CWA in LA laboratory diagnosis.
Most of the time, aPTT-based CWA assay is used. However, CWA could also be valuable with a PT assay. Matsumoto and colleagues used PT-derived CWA in a study intended to show the prediction potential of the bleeding phenotype in patients with acquired anti-factor V inhibitors. 44 They found discriminating differences in the clot time, Clot waveform analysis provides similar information to TGT as it correlates with the rate and velocity of thrombin formation, and reflects the whole process of thrombin generation over time. This contrasts with routine coagulation assays in which clotting time only reflects coagulation initiation. In severe haemophilia or in the presence of a specific factor inhibitor, the rate of thrombin is decreased 53 and this results in statistically significant variations in CWA parameters.
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Increased thrombin generation is observed in thrombophilic states; however, no study correlating CWA parameters and thrombophilic states have been published as yet.
Clot waveform analysis is a global assay which presents many advantages. Based on widely used and very simple assays such as PT and
aPTT, it appears to be easily carried out on widely available automated analysers with optical detection systems, using routine reagents, and is not associated with additional costs for laboratories. In contrast to CWA, thromboelastometric assays and TGT require specific equipment. Furthermore, CWA could be run as a regular routine assay on the same sample as PT and aPTT (0.109 or 0.105 mol/L trisodium citrate blood collection tubes), and with a fast turnaround time compared to other global assays.
As clotting time in aPTT assay occurs when only 5% of thrombin is generated, CWA enables the exploration of the coagulation process with more information than the single clotting time. Throughout studies on DIC, it has been shown that the presence of an abnormal pattern associated with DIC is not influenced by pre-analytical conditions nor by the presence of an anticoagulant. Furthermore, clotting time has no impact on the presence of the biphasic pattern.
However, CWA does have some limitations. As in PT and aPTT assays, the use of whole blood or platelet-rich plasma is not possible.
Using an optical measurement method, interferences colouring plasma such as haemolysis, lipaemia and icterus can impact CWA results.
These interferences depend on the wavelength assigned for optical detection. At present, no study has been run to assess the minimal levels of these interferences to perform CWA in optimal conditions nor the choice of optimal wavelength for clot detection.
Many questions remain open on the potential clinical use of CWA in daily practice. Scientific subcommittees of ISTH proposed standardization using a sensitive optical detection system, colourless and nonopaque reagent and an adjusted normal clotting time for aPTT assay. 
| CONCLUSION
It is now generally accepted that CWA has huge potential and could provide much more information on the haemostasis system than clotting time alone. The most widely used assays are aPTT, and to a lesser extent PT or combined tissue factor plus contact phase activator triggered assays. Efforts have been made to standardize the assay;
however, further recommendations are still needed for an extensive clinical application. At present, HA management and DIC diagnosis and prognosis are the 2 main clinical fields in which CWA is designed to deliver improvements to patient management. Nevertheless, as studies are limited to small cohorts, extensive prospective clinical trials are mandatory to make the leap to clinical application.
